Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial

O'Connor, 2005, Demographics, clinical characteristics, and outcomes of patients hospitalized for decompensated heart failure: observations from the IMPACT-HF registry, J Card Fail, 11, 200, 10.1016/j.cardfail.2004.08.160 Adams, 2005, Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100 000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE), Am Heart J, 149, 209, 10.1016/j.ahj.2004.08.005 Ziaeian, 2016, The prevention of hospital readmissions in heart failure, Prog Cardiovasc Dis, 58, 379, 10.1016/j.pcad.2015.09.004 Bourge, 2008, Randomized controlled trial of an implantable continuous hemodynamic monitor in patients with advanced heart failure: the COMPASS-HF study, J Am Coll Cardiol, 51, 1073, 10.1016/j.jacc.2007.10.061 Abraham, 2011, Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomised controlled trial, Lancet, 377, 658, 10.1016/S0140-6736(11)60101-3 Zile, 2008, Transition from chronic compensated to acute decompensated heart failure: pathophysiological insights obtained from continuous monitoring of intracardiac pressures, Circulation, 118, 1433, 10.1161/CIRCULATIONAHA.108.783910 Abraham, 2017, Implantable hemodynamic monitoring for heart failure patients, J Am Coll Cardiol, 70, 389, 10.1016/j.jacc.2017.05.052 Stevenson, 2010, Chronic ambulatory intracardiac pressures and future heart failure events, Circ Heart Fail, 3, 580, 10.1161/CIRCHEARTFAILURE.109.923300 Abraham, 2016, Sustained efficacy of pulmonary artery pressure to guide adjustment of chronic heart failure therapy: complete follow-up results from the CHAMPION randomised trial, Lancet, 387, 453, 10.1016/S0140-6736(15)00723-0 Zile, 2017, Intracardiac pressures measured using an implantable hemodynamic monitor: relationship to mortality in patients with chronic heart failure, Circ Heart Fail, 10, 1, 10.1161/CIRCHEARTFAILURE.116.003594 Givertz, 2017, Pulmonary artery pressure-guided management of patients with heart failure and reduced ejection fraction, J Am Coll Cardiol, 70, 1875, 10.1016/j.jacc.2017.08.010 Angermann, 2020, Pulmonary artery pressure-guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart Failure (MEMS-HF), Eur J Heart Fail, 22, 1891, 10.1002/ejhf.1943 Shavelle, 2020, Lower rates of heart failure and all-cause hospitalizations during pulmonary artery pressure-guided therapy for ambulatory heart failure: one-year outcomes from the CardioMEMS Post-Approval study, Circ Heart Fail, 13, 10.1161/CIRCHEARTFAILURE.119.006863 Lindenfeld, 2019, Hemodynamic-GUIDEd management of Heart Failure (GUIDE-HF), Am Heart J, 214, 18, 10.1016/j.ahj.2019.04.014 Anker, 2020, Conducting clinical trials in heart failure during (and after) the COVID-19 pandemic: an Expert Consensus Position Paper from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC), Eur Heart J, 41, 2109, 10.1093/eurheartj/ehaa461 Psotka, 2020, Conduct of clinical trials in the era of COVID-19: JACC Scientific Expert Panel, J Am Coll Cardiol, 76, 2368, 10.1016/j.jacc.2020.09.544 Ponikowski, 2020, Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial, Lancet, 396, 1895, 10.1016/S0140-6736(20)32339-4 Cox, 2020, Decreases in acute heart failure hospitalizations during COVID-19, Eur J Heart Fail, 22, 1045, 10.1002/ejhf.1921 Hall, 2020, Reductions in heart failure hospitalizations during the COVID-19 pandemic, J Card Fail, 26, 462, 10.1016/j.cardfail.2020.05.005 Sokolski, 2021, Impact of coronavirus disease 2019 (COVID-19) outbreak on acute admissions at the emergency and cardiology departments across Europe, Am J Med, 134, 482, 10.1016/j.amjmed.2020.08.043 Toner, 2020, Clinical characteristics and trends in heart failure hospitalizations: an Australian experience during the COVID-19 lockdown, JACC Heart Fail, 8, 872, 10.1016/j.jchf.2020.05.014 Cannatà, 2020, Temporal trends in decompensated heart failure and outcomes during COVID-19: a multisite report from heart failure referral centres in London, Eur J Heart Fail, 22, 2219, 10.1002/ejhf.1986 McMurray, 2019, Dapagliflozin in patients with heart failure and reduced ejection fraction, N Engl J Med, 381, 1995, 10.1056/NEJMoa1911303 Solomon, 2019, Angiotensin-neprilysin inhibition in heart failure with preserved ejection fraction, N Engl J Med, 381, 1609, 10.1056/NEJMoa1908655 Packer, 2020, Cardiovascular and renal outcomes with empagliflozin in heart failure, N Engl J Med, 383, 1413, 10.1056/NEJMoa2022190 Nassif, 2019, Dapagliflozin effects on biomarkers, symptoms, and functional status in patients with heart failure with reduced ejection fraction: the DEFINE-HF trial, Circulation, 140, 1463, 10.1161/CIRCULATIONAHA.119.042929 Abraham, 2021, Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes, Eur Heart J, 42, 700, 10.1093/eurheartj/ehaa943